Market Overview

UPDATE: Stifel Upgrades Brooks Automation As Life Sciences Are Key To Growth

Share:
Related BRKS
Brooks Automation and PharmaSeq Announce Licensing Agreement
US Stock Futures Flat Ahead Of Housing Data
Brooks Automation's (BRKS) CEO Stephen Schwartz on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Friday, Stifel analyst Patrick Ho upgraded the rating on Brooks Automation (NASDAQ: BRKS) from Hold to Buy, and named a $13.00 price target.

In the report, Stifel noted, “We are upgrading shares of Brooks Automation from a Hold to a Buy rating and establishing a $13 target price, which we believe reflects a sum-of-parts valuation analysis over the next few years. We are now comfortable with the company's growth prospects in its emerging life sciences business and as we have cited previously, we believe the growth in this area will be the key driver in the overall company's fortunes and the appreciation potential in the stock.”

Brooks Automation closed on Thursday at $9.92.

Latest Ratings for BRKS

DateFirmActionFromTo
Mar 2016Credit SuisseMaintainsUnderperform
Feb 2016B. RileyMaintainsBuy
Aug 2015CitigroupMaintainsNeutral

View More Analyst Ratings for BRKS
View the Latest Analyst Ratings

Posted-In: Patrick Ho StifelAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BRKS)

View Comments and Join the Discussion!